CN110074392A - A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof - Google Patents
A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof Download PDFInfo
- Publication number
- CN110074392A CN110074392A CN201910304163.1A CN201910304163A CN110074392A CN 110074392 A CN110074392 A CN 110074392A CN 201910304163 A CN201910304163 A CN 201910304163A CN 110074392 A CN110074392 A CN 110074392A
- Authority
- CN
- China
- Prior art keywords
- liver
- parts
- stomach
- zinc
- nourishing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 210000002784 stomach Anatomy 0.000 title claims abstract description 38
- 210000000936 intestine Anatomy 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000002075 anti-alcohol Effects 0.000 title abstract description 13
- 239000011701 zinc Substances 0.000 claims abstract description 33
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 32
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 20
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 20
- 241000723418 Carya Species 0.000 claims abstract description 16
- 240000000588 Hericium erinaceus Species 0.000 claims abstract description 16
- 235000007328 Hericium erinaceus Nutrition 0.000 claims abstract description 16
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 15
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 15
- 241001063964 Boletus aereus Species 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 10
- 239000000084 colloidal system Substances 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- 239000011122 softwood Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 33
- 239000006041 probiotic Substances 0.000 abstract description 11
- 235000018291 probiotics Nutrition 0.000 abstract description 11
- 230000001681 protective effect Effects 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 10
- 150000004676 glycans Chemical class 0.000 abstract description 7
- 229920001282 polysaccharide Polymers 0.000 abstract description 7
- 239000005017 polysaccharide Substances 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 2
- 239000001257 hydrogen Substances 0.000 abstract description 2
- 238000005411 Van der Waals force Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 235000019441 ethanol Nutrition 0.000 description 31
- 230000000694 effects Effects 0.000 description 21
- 230000004888 barrier function Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 10
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 8
- 210000005229 liver cell Anatomy 0.000 description 8
- 235000013339 cereals Nutrition 0.000 description 7
- 235000013402 health food Nutrition 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 5
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000005464 sample preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010019837 Hepatocellular injury Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 231100000437 hepatocellular injury Toxicity 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102100026663 All-trans-retinol dehydrogenase [NAD(+)] ADH7 Human genes 0.000 description 1
- 101710193078 All-trans-retinol dehydrogenase [NAD(+)] ADH7 Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003830 Automatism Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 229910000640 Fe alloy Inorganic materials 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- GCNLQHANGFOQKY-UHFFFAOYSA-N [C+4].[O-2].[O-2].[Ti+4] Chemical compound [C+4].[O-2].[O-2].[Ti+4] GCNLQHANGFOQKY-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- KFZAUHNPPZCSCR-UHFFFAOYSA-N iron zinc Chemical compound [Fe].[Zn] KFZAUHNPPZCSCR-UHFFFAOYSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000013252 liver disease animal model Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000005125 simple columnar epithelium Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Abstract
The invention discloses a kind of Antialcoholic liver-protecting nourishing the stomach to protect intestines composition; there are reparation and protective effect to stomach lining using hickory chick, Hericium erinaceus, Boletus aereus; assistant can be with stachyose together as stomach probiotics nutriment with polysaccharide; enteron aisle is directly protected; to indirect protection liver, polysaccharide can also promote the absorption of Zinc-rich saccharomyces cerevisiae, and zinc is the important substance for forming a variety of enzymes in liver; organic zinc in Zinc-rich saccharomyces cerevisiae is more easily absorbed by the body, and liver is directly protected.It complements each other between raw material, a variety of reactions can occur during the preparation process, unexpected pharmacodynamic effects are such as generated to act synergistically by the bonding again of hydrogen bond, Van der Waals force and chemical bond.
Description
Technical field
The invention belongs to technical field of health care food more particularly to a kind of Antialcoholic liver-protecting nourishing the stomach to protect intestines composition, simultaneously also
Provide preparation method.
Background technique
Spirits culture is the important component of Chinese nation's cooking culture, it has also become the indispensable work of people's social activities
Tool.After human body is drunk, alcohol is fat-soluble liquid, without digestion, is directly absorbed into blood rapidly, complete in two hours
It absorbing, wherein 20% alcohol is absorbed by stomach, and has part to carry out first-pass metabolism, remaining 80% is absorbed by duodenum and jejunum,
The alcohol of absorption of human body, which is quickly distributed to whole body, respectively to be organized.Authoritative medical journal " lancet " research, alcohol user gently then cause dusk
It sleeps and various automatisms, it is heavy then even cause alcoholism dead.With going deep into for research, the machine of alcohol harmful to human
It is more and more clear to make.Liver is the major organs for being metabolized alcohol, and alcohol is catalyzed through alcohol dehydrogenase in liver (ADH) and generates second
Aldehyde, acetaldehyde are further oxidized to nontoxic acetic acid by the acetaldehyde dehydrogenase (ALDH) in liver mitochondrion, ultimately generate titanium dioxide
Carbon and energy.But liver metabolism alcohol speed is slow, and alcohol has cytotoxicity, and an excessive consumption of alcohol causes liver to be difficult to fastly
Speed metabolism, alcohol accumulation liver can make liver plasma membrane surface lipids peroxidating, destroy liver plasma membrane, further development can make liver thin
The structures such as micro-pipe and mitochondria intracellular are destroyed, and intracellular metabolic disorder is made, and lead to have cytotoxic metabolism production
Object acetaldehyde generates, so as to cause swelling of liver cell, necrosis.
Stomach is the vitals that ethyl alcohol more early contacts, and ethyl alcohol also becomes domestic and foreign scholars' research to the damage mechanisms of stomach lining
One of important topic.There is pertinent literature confirmation, it is to carry out in liver, but also have small part to exist that ethyl alcohol is metabolized 90% in vivo
It is oxidized in alimentary canal, i.e., is oxidized metabolism in stomach, this phenomenon becomes the first-pass metabolism of ethyl alcohol, its main feature is that for ethyl alcohol
Absorptivity it is very sensitive.Long-term alcohol can make stomach lining alcohol dehydrogenase (ADH) activity decline, and gastric acid is made to reduce and promote
Bacterial growth causes to accelerate gastric emptying, ethyl alcohol is caused to contact reduction with gastric alcohol dehydrogenase (ADH), final to inhibit alcohol in stomach
The first-pass metabolism in portion makes more ethyl alcohol enter blood circulation by intestinal absorption.
Intestinal mucosal barrier is the important immune defense barrier of body, it can by enteron aisle exogenous material and body every
Open, body enable to resist the intrusion of pathogenic microorganism and the damage of antigen molecule, mainly include enterocyte barrier,
Immunization barrier and microbial barrier, midgut epithelial cell barrier are most important one of barriers.And long-term alcohol will lead to intestines
Mucosal villi shortens, or even atrophy phenomenon occurs, keeps intestinal mucosal barrier impaired.Intestinal endotoxin and its activation Hepatic kupffer cells
Inflammatory factor is generated, related document confirms that alcohol serves not only as liver toxic agent, can weaken metabolism and the liver cell of normal liver cell
Stability, damage mitochondrial function, while alcohol can cause intestinal permeability to increase, make gut derived exndotoxin leak to be formed it is secondary
Attack aggravates hepatic injury.
Through state food pharmaceuticals administration general bureau (CFDA) --- health food website " data query " column has been announced
Health food information be data source, and with " having assistant protection function to chemical damage " be keyword carried out China
Ratify health food data collection.Ricipe for health care food type, dosage form, healthcare function, functional component are counted respectively,
It is effectively collected in health food in 325 altogether, while there is " having assistant protection function to chemical damage " and " have to gastric mucosa
The product of assistant protection function " only has 11 kinds, and the health food that three kinds of internal organs of liver sausage stomach are protected there is no.
Edible mushroom is considered to have nutrition, nourishing and pharmacological function.In recent years, the alimentary health-care function of edible mushroom is studied
Very fast development is arrived, modern medicine study shows that edible mushroom primary healthcare function has the organism balance for adjusting human body, improves body
Immunoregulation capability improves blood circulation, enhances cardiovascular function, and prevention cancer cell is formed, and has certain protection to make in liver
With, and have the effects that stomach invigorating is aid digestion.Currently, edible fungus is mainly with the preliminary working product such as dried product, snack food
Main, intensive processing product is few, using modern high technology technique, such as fermentation technique, promotes edible fungi nutrition and health care function
The sustainable development that can be studied.The complicated component of edible mushroom, function are also presented diversified trend, heterogeneity functional characteristics and
The different physiological activity difference of different mushroom substances of the same race is very different, the characteristics of having function diversification, specify ingredient mechanism.
Summary of the invention
The present invention provides a kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof, by hickory chick, Hericium erinaceus, black
Bolete is primary raw material, is aided with Lactobacillus rhamnosus with synergy, stachyose, Zinc-rich saccharomyces cerevisiae, is crushed using broken wall
Technology, full nutrition multicomponent systemization intervene the health food of human liver stomach.By probiotics in paraphyte, enteron aisle screen is repaired
Barrier absorbs edible fungi polysaccharide, improves cytokine levels, and protection stomach lining, is protected liver supplement Zn-ef ficiency, thus
Reduce harm of the ethyl alcohol to human body.Reaching disintoxicating product on alleviation existing market is mainly chemicals and Chinese materia medica preparation, and is changed
Learning class product, there are toxic side effects, and traditional Chinese medicine effect is slow, the bad technical problem of alcohol user's compliance.And fill up no liver
The blank for crowd's product of drinking that stomach is protected jointly.
To achieve the goals above, the present invention adopts the following technical scheme:
Intestines composition is protected in a kind of liver-protecting sobering up nourishing the stomach, it is characterised in that is made of following raw material:
10-30 parts of hickory chick, 10-20 parts of Hericium erinaceus, 10-20 parts of Boletus aereus, 1-10 parts of Lactobacillus rhamnosus, stachyose 1-10
Part, 1-5 parts of Zinc-rich saccharomyces cerevisiae.
Further, Antialcoholic liver-protecting nourishing the stomach shield intestines composition is prepared into tablet health food.
A kind of method for preparing tablet thereof of Antialcoholic liver-protecting nourishing the stomach shield intestines composition, includes the following steps:
Weigh 10-30 parts of hickory chick, 10-20 parts of Hericium erinaceus, 10-20 parts of Boletus aereus, 1-10 parts of Lactobacillus rhamnosus, stachyose
1-10 parts, 1-5 parts of Zinc-rich saccharomyces cerevisiae, are sufficiently mixed to obtain component mixture;Said mixture is carried out by three-dimensional colloid mill
Grinding, minimum grain size are 0.1-1 μm, then by spray drying, mix, softwood processed, granulation, after tabletting, tablet be made.
Six kinds of first wifves such as the selected hickory chick of the present invention, Hericium erinaceus, Boletus aereus expect combination collocation, and proportion is real by animal
Test its reasonability of scientific validation.Raw material is food materials, greatly improves the safety of product, is set about from whole, using edible mushroom,
The full nutrition multicomponent combination solid of the multiple-microorganisms cell such as yeast, probiotics, liquid micronized pulverization technology damage human liver
Wound, gastrointestinal mucosa carry out system intervention, restore it thoroughly.
In prescription of the present invention, hickory chick has help digestion stomach function regulating, liver protection and other effects.Hericium erinaceus, also known as Hericium erinaceus are famous
Dual-purpose of drug and food fungi;It is recorded according to Compendium of Material Medica and " China's book on Chinese herbal medicine ", Hericium erinaceus is mild-natured, sweet in flavor, clinically main at present to use
In treatment gastric duodenal ulcer, chronic gastritis and tumor in digestive tract etc..Boletus aereus has the effects that protect liver, anticancer.Benefit
Raw bacterium can be colonized in enteron aisle, metabolite and active material by formed chemical barrier it is changeable in the pH value of environment, oxygen
Change reduction potential, and then directly inhibit the generation of harmful bacteria, improves the quantity of beneficial bacterium;In addition, probiotics can be made by exclusion
With biological containment is formed, so that harmful bacteria be inhibited to echo production in enteron aisle interior suction, intestinal flora balance is maintained.Related document card
Real, probiotics can stimulate the growth of beneficial bacterium in enteron aisle, and inhibit pathogenic bacteria to grow in enteron aisle through a variety of ways, reduce
The field planting of pathogenic bacteria and Adhering capacity, so as to improve intestinal barrier function.Existing immunological regulation in body can also be adjusted and exempted from
Epidemic disease stimulation inducing macrophage and lymphocyte generate cell factor, improve immunity of organisms.Numerous studies confirm, a variety of
Probiotics has good antioxidant activity and free radical scavenging ability, plays a significant role to body antioxidant levels are improved,
And there are potential protective effects to liver.Lactobacillus rhamnosus is to study a kind of probiotics the most thorough, relative to other
The ability of its environment of resistance to intestinal acidity is stronger for probiotics, only generates Pfansteihl during the fermentation without other acids, therefore
It is without side-effects to human body.It is able to maintain that intestinal flora balance, improves gut barrier function, adjusts immunity of organisms, and to wine
Essence hepatopathy has significant protective effect.Stachyose is as emerging functional oligose, because it is delaying senescence, is adjusting stomach
Intestinal microecology balance has physiological function in terms of improving immunity, Antialcoholic liver-protecting, and development and application is paid more and more attention.
Zinc is one of the essential trace elements of the human body, zinc-deficiency often occurs in patient body and in alcoholic liver disease animal model in excessive drinking
The case where.Clinical research shows that Zn content is lower in the serum and liver of alcoholic liver disease patient, this subtracts with zinc-iron alloy solution in enteron aisle
The excretion of few and urine zinc increases related;The a large amount of liver gene for participating in various kinds of cell function will receive the influence of zinc-deficiency, root
It is past accordingly studies have shown that supplement zinc can prevent caused hepatic injury of indulging in excessive drinking, and liver caused by can controlling because of alcohol aoxidizes
Stress reaction, and play a role in liver regeneration.Zinc-rich saccharomyces cerevisiae is a kind of important zinc nutrition replenishers, it be with
Yeast is carrier, and zinc is independently absorbed and converted during the growth process by yeast, makes zinc and the intracorporal biology point of yeast
Son organically combines, and a kind of zinc of biological state is formed, so that the inorganic zinc and organic zinc that eliminate traditional chemical property are to human body
Toxicity and stomach stimulation, also enable that zinc is more efficient, is more safely absorbed and utilized by the body.
Of the invention has an advantageous effect in that
There are reparation and protective effect to stomach lining using hickory chick, Hericium erinaceus, Boletus aereus, assistant can be with stachyose one with polysaccharide
It rises and is used as stomach probiotics nutriment, enteron aisle is directly protected, thus indirect protection liver, polysaccharide can also promote zinc-rich ferment
Female absorption, zinc are the important substances for forming a variety of enzymes in liver, and the organic zinc in Zinc-rich saccharomyces cerevisiae is more easily absorbed by the body, for liver
It is dirty directly to be protected.It complements each other between raw material, a variety of reactions can occur during the preparation process, such as pass through hydrogen bond, Van der Waals
The bonding again of power and chemical bond generates unexpected pharmacodynamic effects to act synergistically.
Antialcoholic liver-protecting nourishing the stomach shield intestines composition of the present invention crushes the mode combined with liquid cellular using solid cellular,
Under the premise of so that consumer is easier to absorption, maximum remains the activity of the multicomponent among raw material, complete nutrition ingredients and utmostly
Generation pharmacodynamics value, make product better effect.
The use easy to carry of intestines composition is protected in Antialcoholic liver-protecting nourishing the stomach of the present invention, and drug action is obvious, can not only play and relieve the effect of alcohol
The effect of liver protection, but also intestinal flora composed structure can be improved, protective effect is played to gastric mucosa, there is good guarantor
Strong effect.
Detailed description of the invention
Influence of Fig. 1 present composition to AST level in serum;
Influence of Fig. 2 present composition to serum alt level;
The influence that Fig. 3 present composition changes liver pathology;
Influence of Fig. 4 present composition to PEG2 level in stomach;
Influence of Fig. 5 present composition to stomach pathological change;
Influence of Fig. 6 present composition to LPS level in serum;
Influence of Fig. 7 present composition to intestines pathological change.
Specific embodiment
Technical solution of the present invention is described further combined with specific embodiments below, in order to same domain technical staff
Understanding, but do not limit interest field of the invention.
Embodiment 1
It is weighed in the following manner with the parts by weight of each raw material: 10 parts of hickory chick, 20 parts of Hericium erinaceus, 20 parts of Boletus aereus, sandlwood
1 part of sugared lactobacillus, 5 parts of stachyose, 1 part of Zinc-rich saccharomyces cerevisiae, are sufficiently mixed to obtain component mixture.Said mixture is successively passed through
Micronizer and three-dimensional colloid mill are crushed and are ground, and final emulsion minimum grain size is 0.1-1 μm, are then passed through
Spray drying mixes, softwood processed, granulation, after tabletting, tablet is made.
Embodiment 2
It is weighed in the following manner with the parts by weight of each raw material: 20 parts of hickory chick, 10 parts of Hericium erinaceus, 15 parts of Boletus aereus, sandlwood
5 parts of sugared lactobacillus, 1 part of stachyose, 3 parts of Zinc-rich saccharomyces cerevisiae, are sufficiently mixed to obtain component mixture.Said mixture is successively passed through
Micronizer and three-dimensional colloid mill are crushed and are ground, and final emulsion minimum grain size is 0.1-1 μm, are then passed through
Spray drying mixes, softwood processed, granulation, after tabletting, tablet is made.
Embodiment 3
It is weighed in the following manner with the parts by weight of each raw material: 30 parts of hickory chick, 15 parts of Hericium erinaceus, 10 parts of Boletus aereus, sandlwood
10 parts of sugared lactobacillus, 5 parts of stachyose, 5 parts of Zinc-rich saccharomyces cerevisiae, are sufficiently mixed to obtain component mixture.Said mixture is successively led to
It crosses micronizer and three-dimensional colloid mill is crushed and ground, final emulsion minimum grain size is 0.1-1 μm, then logical
Spray drying is crossed, mixes, softwood processed, granulation, after tabletting, tablet be made.
It should be noted that all be substituted for the present composition ingredient technical solution for extracting any combination of raw material
It all belongs to the scope of protection of the present invention.
It is used to illustrate the present composition proportion that optimization obtains by following tests example, and generates unexpected collaboration
Effect can not only play the role of Antialcoholic liver-protecting, but also can improve intestinal flora composed structure, play guarantor to gastric mucosa
Shield effect, has good health-care effect.
1 experimental method
1.1 animal feedings and grouping administration.
This test example is for illustrating that Antialcoholic liver-protecting nourishing the stomach shield intestines composition components of the present invention can not only play Antialcoholic liver-protecting
Effect, but also intestinal flora composed structure can be improved, protective effect is played to gastric mucosa.It is male to prepare health C57BL/6J
Property mouse 70,18~22 g of weight, 23 ± 1 DEG C of raising temperature, relative humidity 55 ± 5% is randomly divided into 7 groups, and every group 10,
Respectively as blank control group, model group, positive group (health promoting liquid being made every effort to overcome, as positive control), example composition group, combination
1(hickory chick, Hericium erinaceus, Boletus aereus), combination 2(hickory chick, Lactobacillus rhamnosus, Zinc-rich saccharomyces cerevisiae), combination 3(rhamnose cream
Bacillus, stachyose, Zinc-rich saccharomyces cerevisiae).
Combine 1 sample preparation methods: 20 parts of hickory chick, 15 parts of Hericium erinaceus, 15 parts of Boletus aereus are sufficiently mixed to obtain component
Mixture.Said mixture is successively passed through to micronizer and three-dimensional colloid mill is crushed and ground, final emulsion
Minimum grain size is 0.1-1 μm, then by spray drying, mix, softwood processed, granulation, after tabletting, tablet be made.
It combines 2 sample preparation methods: weighing 15 parts of hickory chick, 5 parts of Lactobacillus rhamnosus, 3 parts of Zinc-rich saccharomyces cerevisiae, be sufficiently mixed
Obtain component mixture.Said mixture is successively passed through to micronizer and three-dimensional colloid mill is crushed and ground, most
Whole emulsion minimum grain size is 0.1-1 μm, then by spray drying, mix, softwood processed, granulation, after tabletting, tablet be made.
It combines 3 sample preparation methods: weighing 5 parts of Lactobacillus rhamnosus, 5 parts of stachyose, 3 parts of Zinc-rich saccharomyces cerevisiae, be sufficiently mixed
Obtain component mixture.Said mixture is successively passed through to micronizer and three-dimensional colloid mill is crushed and ground, most
Whole emulsion minimum grain size is 0.1-1 μm, then by spray drying, mix, softwood processed, granulation, after tabletting, tablet be made.
10 ml/kg physiological saline are given in blank group stomach-filling when every morning 9, remaining is organized equal stomach-filling and gives 13 g/kg 56
Red Star strong, colourless liquor distilled from sorghum is spent, when afternoon 4,10 ml/kg physiological saline are given in blank group and model group stomach-filling;Power is given in positive group stomach-filling
Gram health promoting liquid;Corresponding sample (800 mg/ of same volume are given in example composition group, combination 1, combination 2 and combination 3
Kg).
The preparation method of 1.4 samples
Medication terminates, and the fasting of each group mouse can't help plucking after 6 h of water eyeball and take blood, blood stand after 30 min 3500 r/min from
10 min of the heart, takes supernatant, is placed in -20 DEG C of refrigerators and saves for use.After blood sampling, by experimental animal put to death, be rapidly separated mouse liver,
Stomach and intestines are saved in -80 DEG C of refrigerators, spare.Some animals stomach is taken, quantitative physiological saline is added and is prepared into 10% liver tissue homogenate
Liquid, it is to be measured.
1.5 pathological study
Liver, stomach and intestines are fixed in formalin, are stored at room temperature.Paraffin embedding, slice and HE dyeing are then carried out, and is passed through
400 times of fluorescence inverted microscopes carry out pathological observation and analysis.
The measurement of 1.6 Some Circulating Factors
According to Shanghai source leaf kit specification, glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminease in each group mice serum are measured
(AST), the level of the factors such as prostaglandin E2 (PGE2), lipopolysaccharides (LPS).
2 interpretations of result
Protective effect of 2.1 compositions to alcohol-induced hepatic injury
AST and ALT: transaminase is the enzyme of transamination between a kind of catalyst vivo acid and ketone acid, clinically often by AST with
Index of the ALT as detection liver function.AST is primarily present in liver cell mitochondria, and ALT is primarily present in liver cell cytoplasm
In, work as hepatocellular injury, the two enzyme can enter blood from liver cell, therefore clinically be usually used in measuring hepatocellular injury degree.
It can be obtained by Fig. 1 and Fig. 2 data, embodiment group AST has significant decrease compared to model group with ALT content, with the positive
Control group is compared reduces 12.82% and 6.56% respectively.Compared to 1-3 group is combined, embodiment group AST and ALT content is minimum.Such as
Shown in Fig. 3, pathological observation the result shows that, control group: liver structure is normal.Model group: fraction necrosis of liver cells is bright
It is aobvious.Positive group: cell infiltration (mostly neutrophil leucocyte) and accidental necrosis of liver cells in visible lobuli hepatis.Combine 1-3 group: can
The micro milling factor of taking a favourable turn infiltration;Embodiment group: normal.On the one hand its reason can significantly reduce in serum with zinc and edible mushroom
Triglycerides and cholesterol level play the role of synergistic correlation to the alleviation of alcoholic fatty liver;Another aspect and sandlwood
Both sugared lactobacillus (probiotics) and stachyose compounding are inhibiting hepatic injury and chronic inflammation side caused by oxidative stress and alcohol
Face has the function of that collaboration is related.Therefore it may be concluded that the present composition is played by the synergistic effect between each component
Preferable hepatoprotective effect.
Protective effect of 2.2 compositions to alcohol-induced gastric injury
Prostaglandin (PGE2) is active material important in gastric mucus, can promote gastric mucus and Bicarbonate secretion, promotes stomach
Mucosa cells update, and improve stomach lining blood circulation, stimulate the release of mucosa surface active phospholipid, have enhancing adaptability thin
Born of the same parents' protective effect is the gastric mucosal protection factor generally acknowledged at present.
It can be obtained by Fig. 4 data, PGE2 content is obviously improved compared to model group, and PGE2 is improved compared with positive controls
48.75%.Compared to 1-3 group is combined, embodiment group PGE2 content highest.
As shown in figure 5, pathological observation the result shows that, control group: liver structure is normal.Model group: epithelium breakage,
Denaturation, necrosis, body of gland mucous modification mucous layer cell infiltration.Positive group: gastric epithelial is damaged, has no other exceptions.Combination
1-3 group: epithelium breakage and slight body of gland mucous modification mucous layer cell infiltration;Embodiment group: gastric epithelial is damaged, has no it
He is abnormal.Its reason and edible mushroom and Lactobacillus rhamnosus form synbiotic, guarantee the stabilization of product, can also improve probiotics
The functionality of product, so that it is related to play anti-ulcer effect.Therefore it can be concluded that, the present composition passes through the association between each component
Same-action plays preferable nourishing the stomach effect.
Protective effect of 2.3 compositions to alcohol-induced damage of intestines
LPS: an important pathogenic factor in alcoholic liver disease, under normal circumstances, due to the defense function of gut barrier,
Only micro endotoxin can penetrate into enteron aisle and enter portal venous circulation, when acute or chronic drink, then can cause peripheral blood
Level of endotoxin significantly increases.It can be inferred that gut barrier injury degree from raised level.
It can be obtained by Fig. 6, embodiment LPS has significant decrease compared with model group, reduces respectively compared with positive controls
3.76%.Compared to 1-3 group is combined, embodiment group acts on the reduction of LPS content in damage of intestines mice serum best.
As shown in fig. 7, pathological observation the result shows that, control group: villus is clear, epithelium be simple columnar epithelium (column
Cell and goblet cell) rule is neat, the visible intestinal glands of submucosa.Model group: each layer structural fuzzy of intestinal wall, epithelium breakage,
Gland cell denaturation, the visible damaged and cell infiltration of fuzzy surface.Positive group: more normal.Combine 1-3 group: visible villus
The visible damaged and cell infiltration in surface;Embodiment group: more normal.It is the reason is as follows that described: edible mushroom, which contains, has biology
Active polysaccharide has improvement result to host intestine flora, can promote the metabolism of profitable strain (such as Bacillus acidi lactici, Bifidobacterium)
And proliferation, while having apparent inhibiting effect to pathogen (such as Escherichia coli, clostridium and salmonella).Enteron aisle benefit
Raw bacterium generates the exocellular polysaccharide being very beneficial to human body while being largely proliferated using stachyose.Two kinds of prebiotics
In conjunction with both improving intestinal environment, protective effect played to enteron aisle normal creepage of gastrointestinal functions and gut barrier, to reach collaboration
Effect.Therefore it may be concluded that the present composition plays preferable shield intestines effect by the synergistic effect between each component.
Claims (2)
1. intestines composition is protected in a kind of liver-protecting sobering up nourishing the stomach, it is characterised in that made of the raw material of following parts by weight:
10-30 parts of hickory chick, 10-20 parts of Hericium erinaceus, 10-20 parts of Boletus aereus, 1-10 parts of Lactobacillus rhamnosus, stachyose 1-10
Part, 1-5 parts of Zinc-rich saccharomyces cerevisiae.
2. a kind of preparation method of liver-protecting sobering up nourishing the stomach shield intestines composition as described in claim 1, includes the following steps:
Weigh 10-30 parts of hickory chick, 10-20 parts of Hericium erinaceus, 10-20 parts of Boletus aereus, 1-10 parts of Lactobacillus rhamnosus, stachyose
1-10 parts, 1-5 parts of Zinc-rich saccharomyces cerevisiae, are sufficiently mixed to obtain component mixture;Said mixture is carried out by three-dimensional colloid mill
Grinding, minimum grain size are 0.1-1 μm, by spray drying, mix, softwood processed, granulation, after tabletting, tablet are made.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910304163.1A CN110074392A (en) | 2019-04-16 | 2019-04-16 | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910304163.1A CN110074392A (en) | 2019-04-16 | 2019-04-16 | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110074392A true CN110074392A (en) | 2019-08-02 |
Family
ID=67415267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910304163.1A Pending CN110074392A (en) | 2019-04-16 | 2019-04-16 | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110074392A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111150067A (en) * | 2020-03-24 | 2020-05-15 | 西安交通大学医学院第一附属医院 | Composition and health food for protecting gastric mucosa |
CN115386016A (en) * | 2022-08-17 | 2022-11-25 | 海南医学院 | Preparation method and application of boletus fuscous crude polysaccharide and chewable tablets thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101837116A (en) * | 2009-03-18 | 2010-09-22 | 安琪酵母股份有限公司 | Liver-protecting and alcoholism-relieving product using Saccharomyces cerevisiae as main material |
CN102920717A (en) * | 2011-08-10 | 2013-02-13 | 高鹏 | Applications of stachyose in hangover alleviating |
CA2991773A1 (en) * | 2015-07-15 | 2017-01-19 | Unigen, Inc. | Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver |
CN109336987A (en) * | 2018-08-30 | 2019-02-15 | 吉林大学 | A kind of hickory chick and bolete compound Thick many candies and preparation method and medical application |
-
2019
- 2019-04-16 CN CN201910304163.1A patent/CN110074392A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101837116A (en) * | 2009-03-18 | 2010-09-22 | 安琪酵母股份有限公司 | Liver-protecting and alcoholism-relieving product using Saccharomyces cerevisiae as main material |
CN102920717A (en) * | 2011-08-10 | 2013-02-13 | 高鹏 | Applications of stachyose in hangover alleviating |
CA2991773A1 (en) * | 2015-07-15 | 2017-01-19 | Unigen, Inc. | Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver |
CN109336987A (en) * | 2018-08-30 | 2019-02-15 | 吉林大学 | A kind of hickory chick and bolete compound Thick many candies and preparation method and medical application |
Non-Patent Citations (2)
Title |
---|
吴晓冰 等: "《解酒醒酒与护肝养胃》", 31 August 2007, 金盾出版社 * |
陈坚 等: "《小细菌大健康——现代社会慢病微生态健康管理》", 30 November 2017, 复旦大学出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111150067A (en) * | 2020-03-24 | 2020-05-15 | 西安交通大学医学院第一附属医院 | Composition and health food for protecting gastric mucosa |
CN115386016A (en) * | 2022-08-17 | 2022-11-25 | 海南医学院 | Preparation method and application of boletus fuscous crude polysaccharide and chewable tablets thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5517215B2 (en) | Fermentation and culture method, plant fermented extract, plant fermented extract powder and blended plant fermented extract | |
CN104982928B (en) | A kind of japanese yew fruit health care ferment and preparation method thereof | |
CN105167072A (en) | Production method of functional Chinese wolfberry fruit enzyme and product thereof | |
CN105192832A (en) | Composition of probiotic fermented horseradish tree leaves as well as preparation method and application of composition | |
JP6684966B2 (en) | Novel Lactobacillus sakei and composition containing the same | |
CN109419814B (en) | Application of paradisella gordonii to inhibition of fatty liver disease | |
CN101836725B (en) | Application of red rice residue product in preparing health-care food for lowering blood fat | |
CN107365680A (en) | A kind of vinegar/vinegar cream prepared using famous brand of wine Daqu and its application | |
CN106729092A (en) | A kind of blood fat reducing preparation containing xylo-oligosaccharide and its preparation method and application | |
CN106413724A (en) | Lactobacillus rhamnosus RHT-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases | |
CN103327995B (en) | For reducing the composition that comprises fermented tea extract of lipid level | |
CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
CN110074392A (en) | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof | |
CN111304134B (en) | Lactobacillus plantarum capable of effectively relieving diabetes | |
JP4602674B2 (en) | Maltase inhibitor | |
CN115044507B (en) | Microbial composition for treating and/or preventing abnormal glycolipid metabolism and application thereof | |
CN114540257B (en) | Lactobacillus crispatus IOB901 and application thereof in aspects of reducing blood sugar and blood fat | |
CN114432337B (en) | Application of cordyceps guangdongensis fruiting body polysaccharide in preparation of medicine for treating and improving obesity and related diseases | |
CN109758485A (en) | Purposes of the russule extract in the preparation of preparation treatment and/or prevention intestinal bacilli illness disease and related disease | |
CN109045070A (en) | A kind of composition for preventing and treating non-alcoholic fatty liver disease | |
CN108653298A (en) | Monosaccharide composition, pharmaceutical preparation and its application | |
WO2021174801A1 (en) | Method for preparing antrodia cinnamomea water-insoluble dietary fibers | |
CN106177227A (en) | A kind of compositions containing coenzyme Q10 strengthening body immunity | |
KR101952991B1 (en) | Fat binder obtained from biomass resulting from beer production | |
KR101054808B1 (en) | Composition for improving cholesterol containing poly-gamma glutamic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |